Accelr8 Announces Extension by NYSE and Acceptance of the Company's Plan to Regain Compliance for Continued Listing on the NYSE Alternext US.

DENVER -- Accelr8 Technology Corporation (NYSE Alternext US: AXK) (the "Company") announced today that on March 18, 2009 it received a notice from the staff (the "Exchange Staff") of NYSE Alternext US LLC (the "NYSE Alternext," which is the successor to the American Stock Exchange) indicating that the Exchange Staff granted a listing extension on the basis of the plan submitted by the Company to regain compliance with listing standards by July 6, 2010. Specifically, the Company has shown how it plans to regain compliance with Section 1003(a)(iii) of the Company Guide with objectives to include stockholders' equity to equal or exceed $6,000,000 and for continuing operations and net income to reverse from losses sustained in its five most recent fiscal years.

About Accelr8

Accelr8 Technology Corporation (www.accelr8.com) is a developer of innovative materials and instrumentation for advanced applications in medical instrumentation, basic research, drug discovery, and bio-detection. Accelr8 is developing rapid clinical pathogen platforms, the BACcel[TM], based on its innovative surface coatings, assay processing, and detection technologies. In addition, Accelr8 licenses certain of its proprietary technology for use in applications outside of Accelr8's own products.

Certain statements in this news release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements regarding future prospects and developments are based upon current expectations and involve certain risks and uncertainties that could cause actual results and developments to differ materially from the forward-looking statement, including those detailed in the company's filings with the Securities and Exchange Commission. Accelr8 does not undertake an obligation to publicly update or revise any forward-looking statements, whether as a result of new information or future events.